🧬At our recent event, we showcased additional Stargardt disease Phase 2 results that shows the potential of Tinlarebant to slow or halt lesion growth. In the 24-month study, 42% of patients with ABCA4 mutations saw no new atrophic lesions and maintained stable QDAF levels. #Tinlarebant #StargardtDisease https://lnkd.in/gf_8ny_W
About us
Belite Bio (NASDAQ: BLTE) is a San Diego based clinical stage drug development company targeting untreatable eye diseases, such as dry AMD and Stargardt disease (STGD1) which is the most common inherited retinal dystrophy, and metabolic diseases. Its lead pipeline, Tinlarebant (aka LBS-008), is a novel oral once-a-day tablet intended to treat Dry AMD and STGD1 early. Tinlarebant is in phase 3 and has been granted Fast Track & RPD designation in the US, and ODD in the US and EMA for STGD1.
- Website
-
http://www.belitebio.com
External link for Belite Bio
- Industry
- Biotechnology Research
- Company size
- 11-50 employees
- Headquarters
- San Diego, California
- Type
- Public Company
- Founded
- 2018
- Specialties
- RBP4, Drug Development, Dry Age-Related Macular Degeneration, Stargardt Disease, Diabetes, NASH, and NAFLD
Locations
-
Primary
Get directions
5820 Oberlin Drive, Suite 101
San Diego, California 92121, US
Employees at Belite Bio
Updates
-
📅 EVENT: Belite Bio (🇺🇸Nasdaq: BLTE) will be presenting at the Association for Research in Vision and Ophthalmology Annual Meeting (ARVO 2024) on May 5, 2024 from 3:45 PM to 4:00 PM PT in Seattle, WA. More Info: https://lnkd.in/gww6gWCu
-
-
🔴NEWS ALERT: Belite Bio (🇺🇸Nasdaq: BLTE) has entered into a securities purchase agreement with an institutional investor. The gross proceeds of the offering is expected to be approximately $25 million. #BeliteBio #News Read More: https://lnkd.in/gFY8vZi3
-
-
REMINDER: Belite Bio (NASDAQ: BLTE) will host a fireside chat on Wednesday, March 13, 2024, at 10:00 am ET at the Leerink Partners Global Biopharma Conference (Webcast). #BeliteBio #Webcast #Leerink 🖥️ Webcast signup: https://lnkd.in/grXGUb2m
-
🔴EARNINGS CALL: Belite Bio (NASDAQ: BLTE) to Host Webcast on Tuesday, March 12, 2024, to Discuss Fourth Quarter and Full Year 2023 Financial Results at 4:30PM Eastern Time (1:30PM PT). Webcast link below. #BeliteBio #EarningsCall 🖥️ Webcast: https://lnkd.in/g8DJCTyQ
-
-
📍NEWS: Belite Bio (NASDAQ: BLTE) will host a fireside chat on Wednesday, March 13, 2024, at 10:00 am ET at the Leerink Partners Global Biopharma Conference (Webcast). #BeliteBio #Webcast #Leerink 🖥️ Webcast signup: https://lnkd.in/grXGUb2m
-
-
🚨Belite Bio will be presenting at the virtual Oppenheimer 34th Annual Healthcare Life Sciences Conference Wed, Feb 14 at 12:40-1:10 PM (ET). Available via webcast. #BeliteBio #Presentation #Oppenheimer34 🔗Learn More: https://lnkd.in/gpxZj_qR
-
-
🎉🎉🎉 Our team at Belite Bio would like to wish you a very happy new year! Thank you for your continued support! Have a great 2024! #BeliteBio #HappyNewYear #2024 🎉🎉🎉
-
-
👁️The eye has a preference for uptake of retinol bound to RBP4. Tinlarebant treatment causes reduced retinol delivery to the eye which slows the accumulation of cytotoxic bisretinoids which have been implicated in loss of vision in STGD1 and GA. #BeliteBio #Tinlarebant #STGD1 #GA
-